News & Events

The Huge Potential of Antibody – Drug Conjugates

Symbiosis Pharmaceutical Services recently attended the World ADC conference in Frankfurt.  There, we were pleased to see 250 attendees from all over the world sharing ideas and reporting their experiences on the progress of ADC development. In combination with the event, World ADC published an insightful market research report  which is available for download by clicking the following link:-http://adcsummit-europe.com/uploads/ffiles/2014/01/659869.pdf.  This article illustrates the predicted future growth of ADCs and, interestingly, also graphs the level of importance which biopharmaceutical companies have placed on ADCs. Despite the numerous technical challenges associated with ADC discovery and development, Symbiosis shares the findings presented in the report and agrees that the future of ADCs is indeed bright.

Chemical and Engineering News recently published an insightful article (https://cen.acs.org/articles/92/i3/Building-Antibody-Drug-Conjugates.html) highlighting the state of the global ADC drug development pipeline and the complexity of the supply chain.  With over 30 ADCs in clinical trials and possibly more than 150 at preclinical stage it’s clear that many companies want a piece of the action, despite there being only 2 ADCs approved by the regulators and on the market.  A key challenge for companies developing ADC’s is in building a network of support through relationships with organisations who can work together bringing respective highly specialist capabilities to deliver the drug product to clinic.

In summary, antibody-drug conjugates continue to represent one of the most exciting new classes of oncology therapeutics and with its experience and technical expertise Symbiosis is looking forward to playing its continued part in facilitating more ADCs entering the clinical trial phase through the use of its world class sterile manufacturing capabilities.

Send an email to contact@symbiosis-pharma.com to discover how we can facilitate your ADC manufacture.  We’ll call you back within 24 hrs.

Get In Touch.


By ticking the box and clicking “Submit” below, you consent to receiving thought leadership, industry news, and invitations by email or other electronic means, which Symbiosis Pharmaceutical Services believes may be of value to you, relevant to your work and tailored to your professional profile and interests. This may include promotional information on products, services and events provided or organised by Symbiosis Pharmaceutical Services. By clicking the "Submit” button, you confirm that the information you have provided above is correct, and you agree to Symbiosis' processing of your personal data, including its transfer internationally and to third parties, in accordance with it's privacy policy.